{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:38:39Z","timestamp":1794494319480,"version":"4.9.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T00:00:00Z","timestamp":1551312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T00:00:00Z","timestamp":1551312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education","id":[{"id":"https:\/\/ror.org\/013aysd81","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Korea Healthcare Technology R&amp;D Project, Ministry of Health &amp; Welfare, Republic of Korea","id":[{"id":"https:\/\/ror.org\/00vxgjw72","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We previously reported that gentisic acid attenuates cardiac hypertrophy and fibrosis in transverse aortic constriction (TAC)-induced cardiac hypertrophy. Here, we examined whether gentisic acid prevents the development of heart failure. Heart failure was induced in mice via chronic TAC. Mice were administered the vehicle, gentisic acid (10 and 100\u2009mg\u2219kg\n                    <jats:sup>\u22121<\/jats:sup>\n                    \u2219day\n                    <jats:sup>\u22121<\/jats:sup>\n                    ), or bisoprolol (0.5\u2009mg\u2219kg\n                    <jats:sup>\u22121<\/jats:sup>\n                    \u2219day\n                    <jats:sup>\u22121<\/jats:sup>\n                    ) orally for 3 weeks, beginning 3 weeks after TAC. After oral administration of gentisic acid (2000 mg\u2219kg\n                    <jats:sup>\u22121<\/jats:sup>\n                    ), no significant differences in organ weight, histology, or analyzed serum and hematological parameters were observed between female mice in the control and gentisic acid-treated groups. Gentisic acid administration inhibited cardiac dysfunction in a dose-dependent manner, and reduced cardiac hypertrophy and fibrosis, as was revealed via western blotting, quantitative real-time PCR, and Masson\u2019s trichrome staining. Gentisic acid dose-dependently reduced the expression of fibrosis marker genes, suppressed the renin-angiotensin-aldosterone system, and reduced lung size and pulmonary vascular remodeling. Our data indicate that gentisic acid prevents cardiac hypertrophy, fibrosis, cardiac dysfunction, and pulmonary pathology in TAC-induced heart failure. These findings suggest that supplementation with gentisic acid may provide an advantage in preventing the progression from cardiac hypertrophy to heart failure.\n                  <\/jats:p>","DOI":"10.1038\/s41598-019-39423-8","type":"journal-article","created":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T06:05:03Z","timestamp":1551333903000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Gentisic acid prevents the transition from pressure overload-induced cardiac hypertrophy to heart failure"],"prefix":"10.1038","volume":"9","author":[{"given":"Simei","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae Jin","family":"Kee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhee","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sin Young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwi Ran","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung-Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Jung","family":"Kee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung Ho","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,28]]},"reference":[{"key":"39423_CR1","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1161\/CIRCHEARTFAILURE.114.001583","volume":"7","author":"AM Shah","year":"2014","unstructured":"Shah, A. M. et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circ Heart Fail 7, 740\u2013751, https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.114.001583 (2014).","journal-title":"Circ Heart Fail"},{"key":"39423_CR2","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.ccl.2007.08.010","volume":"25","author":"RS Velagaleti","year":"2007","unstructured":"Velagaleti, R. S. & Vasan, R. S. Heart failure in the twenty-first century: is it a coronary artery disease or hypertension problem? Cardiol Clin 25, 487\u2013495; v, https:\/\/doi.org\/10.1016\/j.ccl.2007.08.010 (2007).","journal-title":"Cardiol Clin"},{"key":"39423_CR3","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1056\/NEJMp030035","volume":"348","author":"MR Zile","year":"2003","unstructured":"Zile, M. R. & Gaasch, W. H. Heart failure in aortic stenosis - improving diagnosis and treatment. N Engl J Med 348, 1735\u20131736, https:\/\/doi.org\/10.1056\/NEJMp030035 (2003).","journal-title":"N Engl J Med"},{"key":"39423_CR4","doi-asserted-by":"publisher","first-page":"483","DOI":"10.4065\/mcp.2009.0706","volume":"85","author":"K Maganti","year":"2010","unstructured":"Maganti, K., Rigolin, V. H., Sarano, M. E. & Bonow, R. O. Valvular heart disease: diagnosis and management. Mayo Clin Proc 85, 483\u2013500, https:\/\/doi.org\/10.4065\/mcp.2009.0706 (2010).","journal-title":"Mayo Clin Proc"},{"key":"39423_CR5","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/j.jacc.2009.05.015","volume":"54","author":"F Triposkiadis","year":"2009","unstructured":"Triposkiadis, F. et al. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol 54, 1747\u20131762, https:\/\/doi.org\/10.1016\/j.jacc.2009.05.015 (2009).","journal-title":"J Am Coll Cardiol"},{"key":"39423_CR6","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jacc.2009.03.061","volume":"54","author":"JS Floras","year":"2009","unstructured":"Floras, J. S. Sympathetic nervous system activation in human heart failure: clinical implications of an updated model. J Am Coll Cardiol 54, 375\u2013385, https:\/\/doi.org\/10.1016\/j.jacc.2009.03.061 (2009).","journal-title":"J Am Coll Cardiol"},{"key":"39423_CR7","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1042\/CS20130294","volume":"126","author":"IH Zucker","year":"2014","unstructured":"Zucker, I. H., Xiao, L. & Haack, K. K. The central renin-angiotensin system and sympathetic nerve activity in chronic heart failure. Clin Sci (Lond) 126, 695\u2013706, https:\/\/doi.org\/10.1042\/CS20130294 (2014).","journal-title":"Clin Sci (Lond)"},{"key":"39423_CR8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1093\/cvr\/cvq308","volume":"89","author":"EE Creemers","year":"2011","unstructured":"Creemers, E. E. & Pinto, Y. M. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc Res 89, 265\u2013272, https:\/\/doi.org\/10.1093\/cvr\/cvq308 (2011).","journal-title":"Cardiovasc Res"},{"key":"39423_CR9","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1056\/NEJM199705083361903","volume":"336","author":"RS Vasan","year":"1997","unstructured":"Vasan, R. S., Larson, M. G., Benjamin, E. J., Evans, J. C. & Levy, D. Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. N Engl J Med 336, 1350\u20131355, https:\/\/doi.org\/10.1056\/NEJM199705083361903 (1997).","journal-title":"N Engl J Med"},{"key":"39423_CR10","doi-asserted-by":"publisher","first-page":"834","DOI":"10.3238\/arztebl.2016.0834","volume":"113","author":"D Berliner","year":"2016","unstructured":"Berliner, D., Schneider, N., Welte, T. & Bauersachs, J. The Differential Diagnosis of Dyspnea. Dtsch Arztebl Int 113, 834\u2013845, https:\/\/doi.org\/10.3238\/arztebl.2016.0834 (2016).","journal-title":"Dtsch Arztebl Int"},{"key":"39423_CR11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00392-007-0487-y","volume":"96","author":"IC van der Horst","year":"2007","unstructured":"van der Horst, I. C., Voors, A. A. & van Veldhuisen, D. J. Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? Aldosterone receptor antagonists? Clin Res Cardiol 96, 193\u2013195, https:\/\/doi.org\/10.1007\/s00392-007-0487-y (2007).","journal-title":"Clin Res Cardiol"},{"key":"39423_CR12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/cvm-1-2-079","volume":"1","author":"R Willenheimer","year":"2000","unstructured":"Willenheimer, R. Angiotensin receptor blockers in heart failure after the ELITE II trial. Curr Control Trials Cardiovasc Med 1, 79\u201382, https:\/\/doi.org\/10.1186\/cvm-1-2-079 (2000).","journal-title":"Curr Control Trials Cardiovasc Med"},{"key":"39423_CR13","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1093\/eurheartj\/ehs257","volume":"33","author":"F Zannad","year":"2012","unstructured":"Zannad, F. et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J 33, 2782\u20132795, https:\/\/doi.org\/10.1093\/eurheartj\/ehs257 (2012).","journal-title":"Eur Heart J"},{"key":"39423_CR14","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3109\/09637480903517788","volume":"61","author":"P Latocha","year":"2010","unstructured":"Latocha, P., Krupa, T., Wolosiak, R., Worobiej, E. & Wilczak, J. Antioxidant activity and chemical difference in fruit of different Actinidia sp. Int J Food Sci Nutr 61, 381\u2013394, https:\/\/doi.org\/10.3109\/09637480903517788 (2010).","journal-title":"Int J Food Sci Nutr"},{"key":"39423_CR15","doi-asserted-by":"publisher","first-page":"4428","DOI":"10.1021\/jf9029578","volume":"58","author":"R Horax","year":"2010","unstructured":"Horax, R., Hettiarachchy, N. & Chen, P. Extraction, quantification, and antioxidant activities of phenolics from pericarp and seeds of bitter melons (Momordica charantia) harvested at three maturity stages (immature, mature, and ripe). J Agric Food Chem 58, 4428\u20134433, https:\/\/doi.org\/10.1021\/jf9029578 (2010).","journal-title":"J Agric Food Chem"},{"key":"39423_CR16","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1142\/S0192415X18500532","volume":"46","author":"S Sun","year":"2018","unstructured":"Sun, S. et al. Dendropanax morbifera Prevents Cardiomyocyte Hypertrophy by Inhibiting the Sp1\/GATA4 Pathway. Am J Chin Med 46, 1021\u20131044, https:\/\/doi.org\/10.1142\/S0192415X18500532 (2018).","journal-title":"Am J Chin Med"},{"key":"39423_CR17","doi-asserted-by":"publisher","first-page":"4325","DOI":"10.1093\/jxb\/erq234","volume":"61","author":"S Tarraga","year":"2010","unstructured":"Tarraga, S. et al. Molecular cloning and characterization of a novel tomato xylosyltransferase specific for gentisic acid. J Exp Bot 61, 4325\u20134338, https:\/\/doi.org\/10.1093\/jxb\/erq234 (2010).","journal-title":"J Exp Bot"},{"key":"39423_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2891-13-63","volume":"13","author":"BH Juurlink","year":"2014","unstructured":"Juurlink, B. H., Azouz, H. J., Aldalati, A. M., AlTinawi, B. M. & Ganguly, P. Hydroxybenzoic acid isomers and the cardiovascular system. Nutr J 13, 63, https:\/\/doi.org\/10.1186\/1475-2891-13-63 (2014).","journal-title":"Nutr J"},{"key":"39423_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0014-5793(00)01289-8","volume":"470","author":"M Exner","year":"2000","unstructured":"Exner, M. et al. The salicylate metabolite gentisic acid, but not the parent drug, inhibits glucose autoxidation-mediated atherogenic modification of low density lipoprotein. FEBS Lett 470, 47\u201350 (2000).","journal-title":"FEBS Lett"},{"key":"39423_CR20","doi-asserted-by":"publisher","first-page":"11714","DOI":"10.1074\/jbc.M109.064618","volume":"285","author":"IS Fernandez","year":"2010","unstructured":"Fernandez, I. S. et al. Gentisic acid, a compound associated with plant defense and a metabolite of aspirin, heads a new class of in vivo fibroblast growth factor inhibitors. J Biol Chem 285, 11714\u201311729, https:\/\/doi.org\/10.1074\/jbc.M109.064618 (2010).","journal-title":"J Biol Chem"},{"key":"39423_CR21","doi-asserted-by":"publisher","first-page":"5964","DOI":"10.1111\/jcmm.13869","volume":"22","author":"S Sun","year":"2018","unstructured":"Sun, S. et al. Gentisic acid attenuates pressure overload-induced cardiac hypertrophy and fibrosis in mice through inhibition of the ERK1\/2 pathway. J Cell Mol Med 22, 5964\u20135977, https:\/\/doi.org\/10.1111\/jcmm.13869 (2018).","journal-title":"J Cell Mol Med"},{"key":"39423_CR22","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1111\/jcmm.13419","volume":"22","author":"L Jin","year":"2018","unstructured":"Jin, L. et al. Gallic acid attenuates calcium calmodulin-dependent kinase II-induced apoptosis in spontaneously hypertensive rats. J Cell Mol Med 22, 1517\u20131526, https:\/\/doi.org\/10.1111\/jcmm.13419 (2018).","journal-title":"J Cell Mol Med"},{"key":"39423_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-27599-4","volume":"8","author":"L Jin","year":"2018","unstructured":"Jin, L. et al. Gallic acid improves cardiac dysfunction and fibrosis in pressure overload-induced heart failure. Sci Rep 8, 9302, https:\/\/doi.org\/10.1038\/s41598-018-27599-4 (2018).","journal-title":"Sci Rep"},{"key":"39423_CR24","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S0735-1097(01)01210-4","volume":"37","author":"LE Spieker","year":"2001","unstructured":"Spieker, L. E., Noll, G., Ruschitzka, F. T. & Luscher, T. F. Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future? J Am Coll Cardiol 37, 1493\u20131505 (2001).","journal-title":"J Am Coll Cardiol"},{"key":"39423_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13710","volume":"7","author":"J Yang","year":"2016","unstructured":"Yang, J. et al. Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment. Nat Commun 7, 13710, https:\/\/doi.org\/10.1038\/ncomms13710 (2016).","journal-title":"Nat Commun"},{"key":"39423_CR26","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1016\/j.jacc.2016.01.030","volume":"67","author":"D Jeong","year":"2016","unstructured":"Jeong, D. et al. Matricellular Protein CCN5 Reverses Established Cardiac Fibrosis. J Am Coll Cardiol 67, 1556\u20131568, https:\/\/doi.org\/10.1016\/j.jacc.2016.01.030 (2016).","journal-title":"J Am Coll Cardiol"},{"key":"39423_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0925-4773(00)00281-1","volume":"93","author":"J Zhao","year":"2000","unstructured":"Zhao, J. et al. Smad7 is a TGF-beta-inducible attenuator of Smad2\/3-mediated inhibition of embryonic lung morphogenesis. Mech Dev 93, 71\u201381 (2000).","journal-title":"Mech Dev"},{"key":"39423_CR28","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/fsn3.92","volume":"2","author":"PK Gupta","year":"2014","unstructured":"Gupta, P. K., DiPette, D. J. & Supowit, S. C. Protective effect of resveratrol against pressure overload-induced heart failure. Food Sci Nutr 2, 218\u2013229, https:\/\/doi.org\/10.1002\/fsn3.92 (2014).","journal-title":"Food Sci Nutr"},{"key":"39423_CR29","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.vph.2017.10.007","volume":"99","author":"L Jin","year":"2017","unstructured":"Jin, L. et al. Gallic acid attenuates pulmonary fibrosis in a mouse model of transverse aortic contraction-induced heart failure. Vascul Pharmacol 99, 74\u201382, https:\/\/doi.org\/10.1016\/j.vph.2017.10.007 (2017).","journal-title":"Vascul Pharmacol"},{"key":"39423_CR30","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/sj.bjp.0707353","volume":"152","author":"XJ Du","year":"2007","unstructured":"Du, X. J. Divergence of hypertrophic growth and fetal gene profile: the influence of beta-blockers. Br J Pharmacol 152, 169\u2013171, https:\/\/doi.org\/10.1038\/sj.bjp.0707353 (2007).","journal-title":"Br J Pharmacol"},{"key":"39423_CR31","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1016\/j.bbadis.2013.07.003","volume":"1832","author":"IA Sergeeva","year":"2013","unstructured":"Sergeeva, I. A. & Christoffels, V. M. Regulation of expression of atrial and brain natriuretic peptide, biomarkers for heart development and disease. Biochim Biophys Acta 1832, 2403\u20132413, https:\/\/doi.org\/10.1016\/j.bbadis.2013.07.003 (2013).","journal-title":"Biochim Biophys Acta"},{"key":"39423_CR32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1042\/CS20150469","volume":"130","author":"M Volpe","year":"2016","unstructured":"Volpe, M., Carnovali, M. & Mastromarino, V. The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci (Lond) 130, 57\u201377, https:\/\/doi.org\/10.1042\/CS20150469 (2016).","journal-title":"Clin Sci (Lond)"},{"key":"39423_CR33","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1631\/jzus.2005.B0877","volume":"6","author":"N Li","year":"2005","unstructured":"Li, N. & Wang, J. A. Brain natriuretic peptide and optimal management of heart failure. J Zhejiang Univ Sci B 6, 877\u2013884, https:\/\/doi.org\/10.1631\/jzus.2005.B0877 (2005).","journal-title":"J Zhejiang Univ Sci B"},{"key":"39423_CR34","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nrcardio.2016.163","volume":"14","author":"J Hartupee","year":"2017","unstructured":"Hartupee, J. & Mann, D. L. Neurohormonal activation in heart failure with reduced ejection fraction. Nat Rev Cardiol 14, 30\u201338, https:\/\/doi.org\/10.1038\/nrcardio.2016.163 (2017).","journal-title":"Nat Rev Cardiol"},{"key":"39423_CR35","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1111\/j.1525-1497.2004.40402.x","volume":"19","author":"BG Petty","year":"2004","unstructured":"Petty, B. G. The place for ACE inhibitors. J Gen Intern Med 19, 710\u2013711, https:\/\/doi.org\/10.1111\/j.1525-1497.2004.40402.x (2004).","journal-title":"J Gen Intern Med"},{"key":"39423_CR36","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1093\/eurheartj\/ehi204","volume":"26","author":"K Swedberg","year":"2005","unstructured":"Swedberg, K. et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26, 1115\u20131140, https:\/\/doi.org\/10.1093\/eurheartj\/ehi204 (2005).","journal-title":"Eur Heart J"},{"issue":"Suppl D","key":"39423_CR37","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1093\/eurheartj\/15.suppl_D.63","volume":"15","author":"M Paul","year":"1994","unstructured":"Paul, M., Pinto, Y. M., Schunkert, H., Ganten, D. & Bohm, M. Activation of the renin-angiotensin system in heart failure and hypertrophy\u2013studies in human hearts and transgenic rats. Eur Heart J 15(Suppl D), 63\u201367 (1994).","journal-title":"Eur Heart J"},{"key":"39423_CR38","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.2147\/DDDT.S144807","volume":"11","author":"WW Zhang","year":"2017","unstructured":"Zhang, W. W. et al. Edaravone inhibits pressure overload-induced cardiac fibrosis and dysfunction by reducing expression of angiotensin II AT1receptor. Drug Des Devel Ther 11, 3019\u20133033, https:\/\/doi.org\/10.2147\/DDDT.S144807 (2017).","journal-title":"Drug Des Devel Ther"},{"key":"39423_CR39","first-page":"431","volume":"3","author":"P de Groote","year":"2007","unstructured":"de Groote, P., Ennezat, P. V. & Mouquet, F. Bisoprolol in the treatment of chronic heart failure. Vasc Health Risk Manag 3, 431\u2013439 (2007).","journal-title":"Vasc Health Risk Manag"},{"key":"39423_CR40","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1023\/A:1011464510857","volume":"6","author":"P Nambi","year":"2001","unstructured":"Nambi, P., Clozel, M. & Feuerstein, G. Endothelin and heart failure. Heart Fail Rev 6, 335\u2013340 (2001).","journal-title":"Heart Fail Rev"},{"key":"39423_CR41","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10741-012-9365-4","volume":"19","author":"AM Segura","year":"2014","unstructured":"Segura, A. M., Frazier, O. H. & Buja, L. M. Fibrosis and heart failure. Heart Fail Rev 19, 173\u2013185, https:\/\/doi.org\/10.1007\/s10741-012-9365-4 (2014).","journal-title":"Heart Fail Rev"},{"key":"39423_CR42","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1161\/CIRCRESAHA.115.306565","volume":"118","author":"JG Travers","year":"2016","unstructured":"Travers, J. G., Kamal, F. A., Robbins, J., Yutzey, K. E. & Blaxall, B. C. Cardiac Fibrosis: The Fibroblast Awakens. Circulation research 118, 1021\u20131040, https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.306565 (2016).","journal-title":"Circulation research"},{"key":"39423_CR43","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/ajcp\/97.5.669","volume":"97","author":"MW Stanley","year":"1992","unstructured":"Stanley, M. W., Henry-Stanley, M. J., Gajl-Peczalska, K. J. & Bitterman, P. B. Hyperplasia of type II pneumocytes in acute lung injury. Cytologic findings of sequential bronchoalveolar lavage. Am J Clin Pathol 97, 669\u2013677 (1992).","journal-title":"Am J Clin Pathol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-39423-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-39423-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-39423-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T01:41:21Z","timestamp":1671241281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-39423-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,28]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["39423"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-39423-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,28]]},"assertion":[{"value":"6 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"3018"}}